Skip to main content
SpringerLink
Log in

Influence of absorption promoters on pulmonary insulin bioactivity

  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

The purpose of this research was to enhance the bioactivity of insulin by the pulmonary route using a combination of absorption promoters. Aliquots (100 μL) containing 1.0 IU/kg to 7.0 IU/kg doses of porcine insulin solutions with different classes of absorption promoters and combinations of these at 3 concentration levels were instilled intratracheally to the anesthetized rats. Blood concentrations of glucose were measured at specific time points. Out of 3 concentration levels of each of the absorption promoters used, the formulations having the leastconcentration with the maximum percentage of blood glucose reduction were selected for combining absorption promoters, and their pharmacodynamic parameters related to insulin absorption were determined. The pharmacodynamics of porcine insulin following subcutaneous administration of increasing doses were also determined. The relative pulmonary bioactivity of insulin in phosphate buffer pH 7.4 and citrate buffer pH 3.5 was 11.36%±1.27% and 43.20% ±2.48%, respectively, compared to subcutaneous administration. Relative pulmonary bioactivity of 155.60%±5.19% was obtained when oleic acid sodium salt, sodium tauroglycocholate, bestatin, and chymostatin were coadministered in citrate buffer pH 3.5 solution. However, only 61.91%±3.21, 67.09%±3.23%, 67.24%±2.11%, and 69.84%±3.02% were obtained, respectively, upon incorporation of these absorption promoters individually. Absorption promoters in combination have significant potential for increasing the pulmonary bioactivity of insulin. These studies support the argument that pulmonary administration of insulin is a viable alternative to subcutaneous administration for diabetic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jiang G, Qiu W, DeLuca PP. Preparation and in vitro/in vivo evaluation of insulin-loaded poly(acryloyl-hydroxyethyl starch)-PLGA composite microspheres. Pharm Res. 2003;20:452–459.

    Article  CAS  Google Scholar 

  2. Hildebrand GE, Tack TW. Microencapsulation of peptides and proteins. Int J Pharm. 2000;196:173–176.

    Article  CAS  Google Scholar 

  3. Haeckel S, Sachse S, Albayrak C, Müller RH. Preparation and characterization of insulin-loaded microcapsules produced by the induced phase separation method. In: Proceedings of the World Meeting, 1998 APGI/APV, Paris.

  4. Wall DA. Pulmonary absorption of peptides and proteins. Drug Deliv. 1995;2:1–20.

    Article  CAS  Google Scholar 

  5. Stanley SD. Delivery of peptide and non-peptide drugs through the respiratory tract. Pharm Sci Tech Today. 1999;12:450–459.

    Google Scholar 

  6. Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995;12:151–231.

    CAS  Google Scholar 

  7. Patton JS, Trinchero P, Platz RM. Broavailability of pulmonary delivered peptide and protein: interferon alpha, calcitonin and parathyroid hormones. J Control Release. 1994;28:79–85.

    Article  CAS  Google Scholar 

  8. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276:1868–1871.

    Article  CAS  Google Scholar 

  9. Berelowitz M, Becker G. Inhaled insulin: clinical pharmacology and clinical study results. Respir Drug Deliv. 2000;7:151–154.

    Google Scholar 

  10. Clauson PG, Balent B, Okikawa J, et al. PK-PD of four different doses of pulmonary insulin delivered with AERx Diabetes management system. Respir Drug Deliv. 2000;7:155–161.

    Article  Google Scholar 

  11. Adjei A, Hui J, Finley R, Lin T, Fort F. Pulmonary bioavailability of leuprolide acetate following multiple dosing to beagle dogs: some pharmacokinetic and pre-clinical issues. Int J Pharm. 1994;107:57–66.

    Article  CAS  Google Scholar 

  12. Garber RA, Cappelleri JC, Kourides IA, Gelgend RA, Chandler LP, Gorkin L. Improved patient satisfaction with inhaled insulin in subjects with Type I diabetes mellitus: results from a multi-center randomized controlled trial. Diabetes. 1999;48(Suppl 1):A13.

    Google Scholar 

  13. Shyler JS, Cefalu IA, Landschulz WH, Balagtas CC, Cheng SL, Gelfand RA. Efficacy of inhaled insulin in Type 1 diabetes. Lancet. 2002;357:331–335.

    Google Scholar 

  14. Fukuda Y, Tsuji T, Fujita T, Yamamoto A, Muranishi S. Susceptibility of insulin to proteolysis in rat lung homogenate and its protection from proteolysis by various protease inhibitors. Biol Pharm Bull. 1995;18:891–894.

    CAS  Google Scholar 

  15. Suarez S, Garcia L, Sarubbi D, et al. Facilitation of pulmonary insulin absorption by H-MAP: pharmacokinetics and pharmacodynamics in rats. Pharm Res. 2001;18:1677–1684.

    Article  CAS  Google Scholar 

  16. Okumura K, Iwakawa S, Yoshida T, Seki T, Komada F. Intratracheal delivery of insulin: absorption from solution and aerosol by rat lung. Int J Pharm. 1992:88:63–73.

    Article  CAS  Google Scholar 

  17. Liu FY, Shao Z, Kildsig DO, Mitra AK. Pulmonary delivery of free and liposomal insulin. Pharm Res. 1993;10:223–232.

    Article  CAS  Google Scholar 

  18. Enna SJ, Schanker LS. Absorption of saccharides and urea from the rat lung. Am J Physiol. 1972;222:409–414.

    CAS  Google Scholar 

  19. Hyvärinen A, Nikkilä EA. Specific determination of blood glucose with o-toluidine. Clin Chim Acta. 1962;7:142–143.

    Article  Google Scholar 

  20. Gibaldi M, Perri D. Pharmacokinetics. 2nd ed. New York, NY: Marcel Dekker, 1982.

    Google Scholar 

  21. Devore JL, Farnum NR. Applied Statistics for Engineers and Scientists. Pacific Grove, CA, Brooks/Cole Publishing Co; 1999:394–398.

    Google Scholar 

  22. Brange J, Anderson L, Laursen ED, Meyn G, Resmussen E. Towards understanding insulin fibrillation. J Pharm Sci. 1997;86:517–524.

    Article  CAS  Google Scholar 

  23. Brange J, Langkjaer L. Chemical stability of insulin, III: influence of excipients, formulation, and pH. Acta Pharm Nord. 1992;4:149–158.

    CAS  Google Scholar 

  24. Hirai S, Ikenaga T, Matsuzawa T. Nasal absorption of insulin in dogs. Diabetes. 1978;27:296–299.

    Article  CAS  Google Scholar 

  25. Hirai S, Yashiki T, Mima H. Effect of surfactants on the nasal absorption in rats. Int J Pharm. 1981;9:165–172.

    Article  CAS  Google Scholar 

  26. Gordon GS, Moses AC, Silver RD, Flier JS, Carey MC. Nasal absorption of insulin enhancement by bile salts. Proc Natl Acad Sci USA. 1985;82:7419–7423.

    Article  CAS  Google Scholar 

  27. McMartin C, Hutchinson LEF, Hyde R, Peters GE. Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J Pharm Sci. 1987;70:535–540.

    Article  Google Scholar 

  28. Yamomoto A, Hayakawa E, Lee HL. Insulin and pro-insulin proteolysis in mucosal homogenate of the albino rabbit: implications in peptide delivery from non-oral routes. Life Sci. 1990;47:2465–2474.

    Article  Google Scholar 

  29. Khan MJ, Lakshminarayanaiah N, Trotman BW, Chun P, Kaplan SA, Margulies C. Calcium binding and bile salt structure. Hepatology. 1982;2:732.

    Google Scholar 

  30. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Cell adhesion, cell junctions and the extracellular matrix. In: Molecular Biology of the Cell, 2nd edition. New York, Garland Publishing Inc. 1989;791–836.

    Google Scholar 

  31. Patton JS, Bukar J, Nagarajan S. Inhaled insulin. Adv Drug Deliv Rev. 1999;35:235–247.

    Article  CAS  Google Scholar 

  32. Hooper NM. Ectopeptidases. In: Audus KL, Raub TJ, eds. Biological Barriers to Protein Drug Delivery. Pharmaceutical Biotechnology, Vol 4, New York, NY: Kluwer Academic/Plenum Publishers, 1993;23–50.

    Google Scholar 

  33. Takeyama M, Ishida T, Kokubu N, et al. Enhanced bioavailability of subcutaneously injected insulin by pretreatment with ointment containing protease inhibitors. Pharm Res. 1991;8:60–64.

    Article  CAS  Google Scholar 

  34. Okumura K, Komada F, Ryohei H. Fate of porcine and human insulin at the subcutaneous injection site, I: degradation and absorption of insulin in the rat. J Pharmacobiodyn. 1985;8:25–32.

    CAS  Google Scholar 

  35. Hochman J, Artursson P. Mechanism of absorption enhancement and tight junction regulation. J Control Release. 1994;29:253–267.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy Department, Faculty of Technology & Engineering, Kalabhavan, MS University of Baroda, 390 001, Vadodara, Gujarat, India

    T. Mahesh Kumar & Ambikanandan Misra

Authors
  1. T. Mahesh Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ambikanandan Misra
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ambikanandan Misra.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, T.M., Misra, A. Influence of absorption promoters on pulmonary insulin bioactivity. AAPS PharmSciTech 4, 15 (2003). https://doi.org/10.1208/pt040215

Download citation

  • Received:

  • Accepted:

  • DOI: https://doi.org/10.1208/pt040215

Keywords

Search

Navigation